Revenue growth decelerated sharply from 28.0% in 2025Q1 to -79.9% in 2026Q2, with gross margin falling to 10.8% and operating margin contracting to 2.5%, resulting in a net loss of $102.1M.
Jbs N.V. (JBS) annual income statement — 12-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 |
|---|
| Sales/Revenue | 382.19B | 471.14B | 416.95B | 363.82B | 383.97B | 362.5B | 270.2B | 204.52B | 181.68B | 163.17B | 170.38B | 162.91B | 120.47B |
| Revenue Growth % | -16.97% | 13% | 14.61% | -5.25% | 5.92% | 34.16% | 32.11% | 12.57% | 11.34% | -4.23% | 4.58% | 35.23% | - |
| Cost of Goods Sold | 336.87B | 410.82B | 354.18B | 324.17B | 322.93B | 294.01B | 224.99B | 172.58B | 155.34B | 139.4B | 149.07B | 140.32B | 101.8B |
| COGS % of Revenue | - | 87.2% | 84.94% | 89.1% | 84.1% | 81.11% | 83.27% | 84.38% | 85.5% | 85.43% | 87.49% | 86.13% | 84.5% |
| Gross Profit | 45.31B | 60.33B | 62.77B | 39.65B | 61.04B | 68.49B | 45.22B | 31.95B | 26.34B | 23.77B | 21.31B | 22.59B | 18.67B |
| Gross Margin % | 11.86% | 12.8% | 15.06% | 10.9% | 15.9% | 18.89% | 16.73% | 15.62% | 14.5% | 14.57% | 12.51% | 13.87% | 15.5% |
| Gross Profit Growth % | - | -3.9% | 58.32% | -35.04% | -10.87% | 51.46% | 41.54% | 21.28% | 10.8% | 11.53% | -5.65% | 20.98% | - |
| Operating Expenses | 30.62B | 37.7B | 39.01B | 34.35B | 35.75B | 35.14B | 24.77B | 18.5B | 19.18B | 17.04B | 14.73B | 13.47B | 10.48B |
| OpEx % of Revenue | - | 8% | 9.36% | 9.44% | 9.31% | 9.69% | 9.17% | 9.04% | 10.56% | 10.45% | 8.64% | 8.27% | 8.7% |
| Selling, General & Admin | 30.33B | 37.78B | 36.99B | 33.98B | 34.95B | 29.77B | 23.99B | 18.49B | 16.38B | 17.11B | 14.4B | 13.4B | 10.48B |
| SG&A % of Revenue | - | 8.02% | 8.87% | 9.34% | 9.1% | 8.21% | 8.88% | 9.04% | 9.01% | 10.49% | 8.45% | 8.23% | 8.7% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -2M | -78.47M | 2.02B | 368.69M | 798.25M | 5.36B | 778.1M | 5.16M | 2.8B | -69.15M | 325.27M | 66.73M | 0 |
| Operating Income | 14.69B | 22.63B | 23.76B | 5.3B | 25.29B | 33.35B | 20.45B | 13.45B | 7.16B | 6.73B | 6.58B | 9.12B | 8.19B |
| Operating Margin % | 3.84% | 4.8% | 5.7% | 1.46% | 6.59% | 9.2% | 7.57% | 6.58% | 3.94% | 4.12% | 3.86% | 5.6% | 6.8% |
| Operating Income Growth % | - | -4.78% | 348.17% | -79.04% | -24.16% | 63.09% | 52.06% | 87.9% | 6.38% | 2.18% | -27.8% | 11.37% | - |
| EBITDA | 25.86B | 35.25B | 33.46B | 14.06B | 35.38B | 42.68B | 26.85B | 18.54B | 11.93B | 11.17B | 11.06B | 12.79B | 10.74B |
| EBITDA Margin % | 6.77% | 7.48% | 8.02% | 3.86% | 9.21% | 11.77% | 9.94% | 9.06% | 6.57% | 6.85% | 6.49% | 7.85% | 8.91% |
| EBITDA Growth % | -31.02% | 5.37% | 137.94% | -60.26% | -17.09% | 58.94% | 44.83% | 55.34% | 6.8% | 1.04% | -13.52% | 19.13% | - |
| D&A (Non-Cash Add-back) | 11.16B | 12.63B | 9.69B | 8.76B | 10.09B | 9.33B | 6.4B | 5.09B | 4.78B | 4.45B | 4.48B | 3.67B | 2.55B |
| EBIT | 15.8B | 23.58B | 25.69B | 5.96B | 25.89B | 33.65B | 21.27B | 13.2B | 7.33B | 6.69B | 7.04B | 9.12B | 7.81B |
| Net Interest Income | -5.04B | -6.88B | -1.19B | -1.41B | -1.07B | -830.84M | -3.77B | -4.07B | -3.65B | -4.5B | -3.32B | -2.46B | -2.61B |
| Interest Income | 907.36M | 2.3B | 453.73M | 326.44M | 268.42M | 144.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.95B | 9.18B | 1.65B | 1.73B | 1.34B | 975.16M | 3.77B | 4.07B | 3.65B | 4.5B | 3.32B | 2.46B | 2.61B |
| Other Income/Expense | -6.92B | -8.23B | -8.94B | -6.7B | -6.5B | -5.13B | -12.19B | -5.95B | -8.26B | -5.58B | -6.29B | -1.24B | -4B |
| Pretax Income | 7.77B | 14.4B | 14.82B | -1.4B | 18.79B | 28.22B | 8.26B | 7.5B | -1.1B | 1.15B | 290.82M | 7.88B | 4.19B |
| Pretax Margin % | 2.03% | 3.06% | 3.55% | -0.38% | 4.89% | 7.78% | 3.06% | 3.67% | -0.6% | 0.71% | 0.17% | 4.84% | 3.48% |
| Income Tax | 801.49M | 2.17B | 4.12B | -668.94M | 2.17B | 6.93B | 3.61B | 1.03B | -1.31B | 126.29M | -274.26M | 2.75B | 1.79B |
| Effective Tax Rate % | 10.32% | 15.09% | 27.78% | 47.85% | 11.54% | 24.57% | 43.67% | 13.78% | 119.13% | 10.96% | -94.31% | 34.9% | 42.59% |
| Net Income | 6.41B | 11.1B | 9.62B | -1.06B | 15.85B | 21.24B | 4.6B | 6.07B | 25.2M | 534.2M | 233.56M | 4.64B | 2.04B |
| Net Margin % | 1.68% | 2.36% | 2.31% | -0.29% | 4.13% | 5.86% | 1.7% | 2.97% | 0.01% | 0.33% | 0.14% | 2.85% | 1.69% |
| Net Income Growth % | -47.54% | 15.4% | 1006.33% | -106.69% | -25.38% | 361.95% | -24.22% | 23981.78% | -95.28% | 128.72% | -94.97% | 127.91% | - |
| Net Income (Continuing) | 6.97B | 12.23B | 10.7B | -729.14M | 16.62B | 21.28B | 4.65B | 6.46B | 210.12M | 1.03B | 565.09M | 5.13B | 2.41B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 834.76M | 4.51B | 34.57B | 17.93B | 3.46B | 3.68B | 3.42B | 2.85B | 2.3B | 1.85B | 1.14B | 1.59B | 1.77B |
| EPS (Diluted) | 6.28 | 10.41 | 0.80 | -0.48 | 7.09 | 8.58 | 1.73 | 2.28 | 0.01 | 0.19 | 0.09 | 1.60 | 0.71 |
| EPS Growth % | 12.34% | 1201.25% | 266.67% | -106.77% | -17.37% | 395.95% | -24.12% | - | -95% | 121.45% | -94.64% | 125.35% | - |
| EPS (Basic) | - | 10.41 | 0.80 | -0.48 | 7.09 | 8.58 | 1.73 | 2.28 | 0.01 | 0.19 | 0.09 | 1.60 | 0.71 |
| Diluted Shares Outstanding | 1.02B | 1.07B | 2.22B | 2.22B | 2.25B | 2.48B | 2.66B | 2.67B | 2.67B | 2.85B | 2.73B | 2.9B | 2.88B |
| Basic Shares Outstanding | 1.02B | 1.07B | 2.22B | 2.22B | 2.25B | 2.48B | 2.66B | 2.66B | 2.66B | 2.83B | 2.72B | 2.9B | 2.88B |
| Dividend Payout Ratio | - | 79.38% | 46.14% | - | 27.99% | 34.82% | 31.34% | 0.1% | 503.52% | 17.48% | 471.89% | 10.4% | 10.8% |
Quick answers to the most common questions about buying JBS stock.
For fiscal year 2025, Jbs N.V. (JBS) reported total revenue of $471.14B. This represents a 291.1% increase compared to $120.47B in 2014.
Jbs N.V. (JBS) is profitable, generating $11.10B in net income for the fiscal year ending 2025 with a net profit margin of 2.4%.
Jbs N.V. (JBS) reported an operating income of $22.63B, resulting in an operating profit margin of 4.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Jbs N.V. (JBS) generated $60.33B in gross profit for the year, representing a gross profit margin of 12.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
High leverage and margin compression
Metrics are mathematically derived from official filings.
Revenue Momentum Fades Sharply
Revenue growth decelerated from 28.0% in 2025Q1 to -79.9% in 2026Q2, with reported revenue collapsing to $23.9B from $119.0B a year earlier, according to the latest quarterly data.
The dramatic revenue decline in 2026Q2 appears to reflect a significant change in reporting or a one-off event, as the sequential drop from $111.5B in 2026Q1 is unprecedented. This suggests that the underlying business may be facing severe demand destruction or that the company has divested major operations, though the data does not specify. Investors should monitor whether this is a structural shift or a temporary anomaly, as the prior quarters showed robust double-digit growth.
Gross Margin Erosion Accelerates
Gross margin fell from 16.5% in 2024Q3 to 10.8% in 2026Q2, a 570 basis point contraction, reflecting intense input cost pressure and limited pricing power, as reported in the income statement data.
The persistent decline in gross margin, despite revenue growth in earlier quarters, indicates that JBS is unable to pass through higher livestock and feed costs to customers. The 2026Q2 gross margin of 10.8% is below the peer average, with Tyson at 6.5% and Hormel at 15.6%, suggesting JBS is losing its cost advantage. This margin compression is likely to persist given the tight US cattle supply and record feeder cattle prices, which may continue to pressure the beef segment.
Operating Leverage Reverses
Operating income swung from $8.6B in 2024Q3 to $597M in 2026Q2, with operating margin contracting from 7.8% to 2.5%, indicating that fixed costs are no longer being absorbed by revenue growth.
The sharp decline in operating income, despite relatively stable SG&A as a percentage of revenue, suggests that the company's cost structure is not flexible enough to adapt to the revenue downturn. In 2026Q2, SG&A of $2.0B on $23.9B revenue implies an SG&A ratio of 8.4%, which is higher than the 7-8% range seen in prior quarters, indicating that overhead costs are not scaling down with revenue. This reversal of operating leverage may indicate that the company's cost base is too rigid for the current demand environment.
Earnings Quality Deteriorates
Net income turned negative at -$102.1M in 2026Q2, with EPS of -$0.09 versus an estimate of $2.13, while stock-based compensation of $101.8M adds to the earnings drag, based on the latest quarterly report.
The significant EPS miss and the negative net income in 2026Q2 raise concerns about the quality of earnings, as the company may be incurring non-operating charges or impairments that are not fully disclosed. The presence of stock-based compensation, which was zero in 2026Q1, suggests that the company may be using equity-based incentives to preserve cash, which could dilute shareholders. Investors should scrutinize the sustainability of earnings, as the current profitability appears to be below the cost of capital.
Cost Pressures Intensify
COGS as a percentage of revenue rose to 89.2% in 2026Q2 from 83.5% in 2024Q3, indicating that input costs are consuming a larger share of sales, as per the income statement data.
The rising COGS ratio highlights the company's vulnerability to commodity price fluctuations, particularly in beef and poultry feed. While SG&A has remained relatively stable in absolute terms, the increase in COGS has more than offset any operational efficiencies, leading to a gross profit decline of over 80% year-over-year in 2026Q2. This suggests that management's cost discipline is being overwhelmed by external cost pressures, and without a recovery in livestock cycles, margins may remain under pressure.
What Could Invalidate the Bull Case
The 2026Q2 revenue collapse and negative EPS suggest that the company may be facing a structural break, not just cyclical headwinds, which could challenge the narrative of a diversified global protein platform.
Short-sellers might argue that the dramatic revenue decline and margin compression indicate that JBS's multi-protein diversification is not providing the expected resilience, and that the company's high leverage (Debt/Equity of 2.40) could become a solvency risk if earnings do not recover. The absence of formal guidance and the unexplained revenue drop warrant caution, as it may signal undisclosed operational issues or accounting changes. If the company cannot restore profitability to prior levels, the stock could face further de-rating.